Sylvant FDA Approval History
FDA Approved: Yes (First approved April 22, 2014)
Brand name: Sylvant
Generic name: siltuximab
Dosage form: for Injection
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Multicentric Castleman's Disease
Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman’s disease.
Development timeline for Sylvant
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
